Acadia Pharma (ACAD) Misses Q4 EPS by 1c

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $0.28, $0.01 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $231 million versus the consensus estimate of $223.77 million.

Full Year 2024 Financial Guidance

• DAYBUE net product sales in the range of $370 to $420 million.
• NUPLAZID net product sales in the range of $560 to $590 million.
• GAAP R&D expense in the range of $305 to $325 million.
• GAAP SG&A expense in the range of $455 to $480 million.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance
• La-Z-Boy (LZB) Misses Q1 EPS by 6c, Misses on Revenue; Offers Weak Q2 Revenue Guidance
• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance